Natural Product (NP) Details
General Information of the NP (ID: NP3125) | |||||
---|---|---|---|---|---|
Name |
Procyanidin
|
||||
Synonyms |
2-(3,4-Dihydroxyphenyl)-2-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-3-yl)oxy)chroman-3,4,5,7-tetraol; 2-(3,4-dihydroxyphenyl)-2-[[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl]oxy]-3,4-dihydrochromene-3,4,5,7-tetrol; 2H-1-Benzopyran-3,4,5,7-tetrol, 2-(3,4-dihydroxyphenyl)-2-((2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl)oxy)-3,4-dihydro-; Procyanidins; 2H-1-Benzopyran-3,4,5,7-tetrol, 2-(3,4-dihydroxyphenyl)-2-[[2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl]oxy]-3,4-dihydro-; BRN 1675863; 2-(3,4-Dihydroxyphenyl)-2-((2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl)oxy)-3,4-dihydro-2H-1-benzopyran-3,4,5,7-tetrol; 3,3',4,4',5,7-Flavanhexol, 2-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-chromanyl)oxy)-; Procyanidin, Technical grade; SCHEMBL15091123; DTXSID90858698; CHEBI:166895; BCP25503; HY-N0794; C31H28O12; MFCD01662851; s5105; AKOS025402316; AC-8032; CCG-270176; CCG-270178; 2-(3,4-dihydroxyphenyl)-2-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl]oxy-chromane-3,4,5,7-tetrol; AK321485; CS-0009805; FT-0688150; X1211; Y0170; 852P226; 2-(3,4-dihydroxyphenyl)-2-{[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2h-chromen-3-yl]oxy}-3,4,5,7-chromanetetrol
Click to Show/Hide
|
||||
Species Origin | Cinnamomum camphora ... | Click to Show/Hide | |||
Cinnamomum camphora | |||||
Fagopyrum dibotrys | |||||
Flemingia macrophylla | |||||
Disease | Breast cancer [ICD-11: 2C60] | Phase 2 | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C30H26O13
|
||||
PubChem CID | |||||
Canonical SMILES |
C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC4(C(C(C5=C(C=C(C=C5O4)O)O)O)O)C6=CC(=C(C=C6)O)O
|
||||
InChI |
1S/C30H26O13/c31-14-7-19(35)16-11-25(28(41-23(16)9-14)12-1-3-17(33)20(36)5-12)43-30(13-2-4-18(34)21(37)6-13)29(40)27(39)26-22(38)8-15(32)10-24(26)42-30/h1-10,25,27-29,31-40H,11H2
|
||||
InChIKey |
HGVVOUNEGQIPMS-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 20347-71-1
|
||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Caco-2 | CVCL_0025 | Colon adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Procyanidin enhances the impact of 5-Fluorouracil chemotherapy on Caco-2 human colon cancer cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Caspase-3 (CASP3) | Molecule Info | [3] | |
Cellular tumor antigen p53 (TP53) | Molecule Info | [3] | ||
DNA-binding factor KBF1 (p105) | Molecule Info | [4] | ||
Protein kinase B alpha (AKT1) | Molecule Info | [5] | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | Rap1 signaling pathway | |||
5 | cGMP-PKG signaling pathway | |||
6 | cAMP signaling pathway | |||
7 | Chemokine signaling pathway | |||
8 | HIF-1 signaling pathway | |||
9 | FoxO signaling pathway | |||
10 | Sphingolipid signaling pathway | |||
11 | mTOR signaling pathway | |||
12 | PI3K-Akt signaling pathway | |||
13 | AMPK signaling pathway | |||
14 | Apoptosis | |||
15 | Adrenergic signaling in cardiomyocytes | |||
16 | VEGF signaling pathway | |||
17 | Osteoclast differentiation | |||
18 | Focal adhesion | |||
19 | Tight junction | |||
20 | Signaling pathways regulating pluripotency of stem cells | |||
21 | Platelet activation | |||
22 | Toll-like receptor signaling pathway | |||
23 | Jak-STAT signaling pathway | |||
24 | T cell receptor signaling pathway | |||
25 | B cell receptor signaling pathway | |||
26 | Fc epsilon RI signaling pathway | |||
27 | Fc gamma R-mediated phagocytosis | |||
28 | TNF signaling pathway | |||
29 | Neurotrophin signaling pathway | |||
30 | Cholinergic synapse | |||
31 | Dopaminergic synapse | |||
32 | Insulin signaling pathway | |||
33 | Progesterone-mediated oocyte maturation | |||
34 | Estrogen signaling pathway | |||
35 | Prolactin signaling pathway | |||
36 | Thyroid hormone signaling pathway | |||
37 | Adipocytokine signaling pathway | |||
38 | Glucagon signaling pathway | |||
39 | Regulation of lipolysis in adipocytes | |||
40 | Non-alcoholic fatty liver disease (NAFLD) | |||
41 | Carbohydrate digestion and absorption | |||
42 | Chagas disease (American trypanosomiasis) | |||
43 | Toxoplasmosis | |||
44 | Tuberculosis | |||
45 | Hepatitis C | |||
46 | Hepatitis B | |||
47 | Measles | |||
48 | Influenza A | |||
49 | HTLV-I infection | |||
50 | Epstein-Barr virus infection | |||
51 | Pathways in cancer | |||
52 | Proteoglycans in cancer | |||
53 | Colorectal cancer | |||
54 | Renal cell carcinoma | |||
55 | Pancreatic cancer | |||
56 | Endometrial cancer | |||
57 | Glioma | |||
58 | Prostate cancer | |||
59 | Melanoma | |||
60 | Chronic myeloid leukemia | |||
61 | Acute myeloid leukemia | |||
62 | Small cell lung cancer | |||
63 | Non-small cell lung cancer | |||
64 | Central carbon metabolism in cancer | |||
65 | Choline metabolism in cancer | |||
66 | Cell cycle | |||
67 | p53 signaling pathway | |||
68 | Wnt signaling pathway | |||
69 | Amyotrophic lateral sclerosis (ALS) | |||
70 | Huntington's disease | |||
71 | Herpes simplex infection | |||
72 | Transcriptional misregulation in cancer | |||
73 | Viral carcinogenesis | |||
74 | MicroRNAs in cancer | |||
75 | Thyroid cancer | |||
76 | Basal cell carcinoma | |||
77 | Bladder cancer | |||
78 | Natural killer cell mediated cytotoxicity | |||
79 | Serotonergic synapse | |||
80 | Alzheimer's disease | |||
81 | Parkinson's disease | |||
82 | Epithelial cell signaling in Helicobacter pylori infection | |||
83 | Pertussis | |||
84 | Legionellosis | |||
85 | Amoebiasis | |||
86 | Viral myocarditis | |||
87 | NF-kappa B signaling pathway | |||
88 | NOD-like receptor signaling pathway | |||
89 | RIG-I-like receptor signaling pathway | |||
90 | Cytosolic DNA-sensing pathway | |||
91 | Cocaine addiction | |||
92 | Shigellosis | |||
93 | Salmonella infection | |||
94 | Leishmaniasis | |||
95 | Inflammatory bowel disease (IBD) | |||
NetPath Pathway | TSH Signaling Pathway | Click to Show/Hide | ||
2 | FSH Signaling Pathway | |||
3 | TCR Signaling Pathway | |||
4 | IL2 Signaling Pathway | |||
5 | IL4 Signaling Pathway | |||
6 | IL5 Signaling Pathway | |||
7 | IL1 Signaling Pathway | |||
8 | TNFalpha Signaling Pathway | |||
9 | Leptin Signaling Pathway | |||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | Apoptosis signaling pathway | |||
3 | EGF receptor signaling pathway | |||
4 | Endothelin signaling pathway | |||
5 | FGF signaling pathway | |||
6 | Huntington disease | |||
7 | Hypoxia response via HIF activation | |||
8 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
9 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
10 | Interleukin signaling pathway | |||
11 | PI3 kinase pathway | |||
12 | T cell activation | |||
13 | VEGF signaling pathway | |||
14 | p53 pathway | |||
15 | Ras Pathway | |||
16 | p53 pathway by glucose deprivation | |||
17 | p53 pathway feedback loops 2 | |||
18 | CCKR signaling map ST | |||
19 | Wnt signaling pathway | |||
20 | P53 pathway feedback loops 1 | |||
21 | FAS signaling pathway | |||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
3 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
4 | Insulin Signalling | |||
5 | Leucine Stimulation on Insulin Signaling | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Fc-epsilon receptor I signaling in mast cells | |||
3 | Endothelins | |||
4 | BCR signaling pathway | |||
5 | LPA receptor mediated events | |||
6 | Insulin Pathway | |||
7 | IL4-mediated signaling events | |||
8 | TCR signaling in naï | |||
9 | ||||
10 | Plasma membrane estrogen receptor signaling | |||
11 | CD40/CD40L signaling | |||
12 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
13 | Signaling events mediated by PTP1B | |||
14 | S1P3 pathway | |||
15 | Coregulation of Androgen receptor activity | |||
16 | Reelin signaling pathway | |||
17 | Integrin-linked kinase signaling | |||
18 | TCR signaling in naï | |||
19 | ||||
20 | Angiopoietin receptor Tie2-mediated signaling | |||
21 | FAS (CD95) signaling pathway | |||
22 | Thromboxane A2 receptor signaling | |||
23 | Regulation of Telomerase | |||
24 | FOXA2 and FOXA3 transcription factor networks | |||
25 | Glucocorticoid receptor regulatory network | |||
26 | mTOR signaling pathway | |||
27 | CXCR4-mediated signaling events | |||
28 | IGF1 pathway | |||
29 | FoxO family signaling | |||
30 | IL2 signaling events mediated by PI3K | |||
31 | Ceramide signaling pathway | |||
32 | p75(NTR)-mediated signaling | |||
33 | E-cadherin signaling in the nascent adherens junction | |||
34 | amb2 Integrin signaling | |||
35 | Integrins in angiogenesis | |||
36 | IFN-gamma pathway | |||
37 | ErbB1 downstream signaling | |||
38 | ErbB2/ErbB3 signaling events | |||
39 | IL6-mediated signaling events | |||
40 | E-cadherin signaling in keratinocytes | |||
41 | Nephrin/Neph1 signaling in the kidney podocyte | |||
42 | Retinoic acid receptors-mediated signaling | |||
43 | IL8- and CXCR2-mediated signaling events | |||
44 | Signaling events mediated by the Hedgehog family | |||
45 | Nongenotropic Androgen signaling | |||
46 | Hedgehog signaling events mediated by Gli proteins | |||
47 | Caspase Cascade in Apoptosis | |||
48 | CXCR3-mediated signaling events | |||
49 | VEGFR1 specific signals | |||
50 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
51 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
52 | a6b1 and a6b4 Integrin signaling | |||
53 | Aurora A signaling | |||
54 | Insulin-mediated glucose transport | |||
55 | Class I PI3K signaling events mediated by Akt | |||
56 | IL8- and CXCR1-mediated signaling events | |||
57 | HIF-1-alpha transcription factor network | |||
58 | p53 pathway | |||
59 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
60 | VEGFR3 signaling in lymphatic endothelium | |||
61 | FGF signaling pathway | |||
62 | Signaling events mediated by HDAC Class III | |||
63 | Validated targets of C-MYC transcriptional activation | |||
64 | LKB1 signaling events | |||
65 | Direct p53 effectors | |||
66 | AP-1 transcription factor network | |||
67 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | |||
68 | Signaling mediated by p38-alpha and p38-beta | |||
69 | BARD1 signaling events | |||
70 | PLK3 signaling events | |||
71 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
72 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
73 | Posttranslational regulation of adherens junction stability and dissassembly | |||
74 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
75 | Syndecan-2-mediated signaling events | |||
76 | Atypical NF-kappaB pathway | |||
77 | Canonical NF-kappaB pathway | |||
78 | IL12-mediated signaling events | |||
79 | Alternative NF-kappaB pathway | |||
80 | Osteopontin-mediated events | |||
81 | Signaling events mediated by HDAC Class I | |||
82 | IL1-mediated signaling events | |||
83 | TNF receptor signaling pathway | |||
84 | IL23-mediated signaling events | |||
85 | EPO signaling pathway | |||
Reactome | Activation of BAD and translocation to mitochondria | Click to Show/Hide | ||
2 | GPVI-mediated activation cascade | |||
3 | PIP3 activates AKT signaling | |||
4 | Translocation of GLUT4 to the plasma membrane | |||
5 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||
6 | AKT phosphorylates targets in the cytosol | |||
7 | AKT phosphorylates targets in the nucleus | |||
8 | Negative regulation of the PI3K/AKT network | |||
9 | eNOS activation | |||
10 | AKT-mediated inactivation of FOXO1A | |||
11 | Integrin alphaIIb beta3 signaling | |||
12 | Deactivation of the beta-catenin transactivating complex | |||
13 | CD28 dependent PI3K/Akt signaling | |||
14 | CTLA4 inhibitory signaling | |||
15 | G beta:gamma signalling through PI3Kgamma | |||
16 | KSRP (KHSRP) binds and destabilizes mRNA | |||
17 | VEGFR2 mediated vascular permeability | |||
18 | TP53 Regulates Metabolic Genes | |||
19 | Constitutive Signaling by AKT1 E17K in Cancer | |||
20 | Activation of NOXA and translocation to mitochondria | |||
21 | Activation of PUMA and translocation to mitochondria | |||
22 | Pre-NOTCH Transcription and Translation | |||
23 | Oxidative Stress Induced Senescence | |||
24 | Formation of Senescence-Associated Heterochromatin Foci (SAHF) | |||
25 | Oncogene Induced Senescence | |||
26 | DNA Damage/Telomere Stress Induced Senescence | |||
27 | Autodegradation of the E3 ubiquitin ligase COP1 | |||
28 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||
29 | Stabilization of p53 | |||
30 | Factors involved in megakaryocyte development and platelet production | |||
31 | SMAC binds to IAPs | |||
32 | SMAC-mediated dissociation of IAP:caspase complexes | |||
33 | Apoptotic cleavage of cellular proteins | |||
34 | Degradation of the extracellular matrix | |||
35 | NADE modulates death signalling | |||
36 | Activation of DNA fragmentation factor | |||
37 | Caspase-mediated cleavage of cytoskeletal proteins | |||
38 | Activation of NF-kappaB in B cells | |||
39 | RIP-mediated NFkB activation via ZBP1 | |||
40 | Regulated proteolysis of p75NTR | |||
41 | NF-kB is activated and signals survival | |||
42 | Senescence-Associated Secretory Phenotype (SASP) | |||
43 | FCERI mediated NF-kB activation | |||
44 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||
45 | Transcriptional regulation of white adipocyte differentiation | |||
46 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
47 | Interleukin-1 processing | |||
48 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||
49 | IkBA variant leads to EDA-ID | |||
50 | CLEC7A (Dectin-1) signaling | |||
51 | CD209 (DC-SIGN) signaling | |||
52 | CLEC7A/inflammasome pathway | |||
53 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
54 | TRAF6 mediated NF-kB activation | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | DNA Damage Response (only ATM dependent) | |||
3 | TCR Signaling Pathway | |||
4 | Notch Signaling Pathway | |||
5 | EPO Receptor Signaling | |||
6 | IL-2 Signaling Pathway | |||
7 | Insulin Signaling | |||
8 | Endochondral Ossification | |||
9 | EGF/EGFR Signaling Pathway | |||
10 | IL-4 Signaling Pathway | |||
11 | TGF beta Signaling Pathway | |||
12 | IL-6 signaling pathway | |||
13 | Wnt Signaling Pathway Netpath | |||
14 | Copper homeostasis | |||
15 | Extracellular vesicle-mediated signaling in recipient cells | |||
16 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
17 | IL-3 Signaling Pathway | |||
18 | Cardiac Hypertrophic Response | |||
19 | Translocation of GLUT4 to the Plasma Membrane | |||
20 | Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||
21 | PIP3 activates AKT signaling | |||
22 | Signal Transduction of S1P Receptor | |||
23 | T-Cell Receptor and Co-stimulatory Signaling | |||
24 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
25 | Apoptosis | |||
26 | Alpha 6 Beta 4 signaling pathway | |||
27 | BDNF signaling pathway | |||
28 | Integrated Pancreatic Cancer Pathway | |||
29 | Oncostatin M Signaling Pathway | |||
30 | Corticotropin-releasing hormone | |||
31 | Interleukin-11 Signaling Pathway | |||
32 | AGE/RAGE pathway | |||
33 | TNF alpha Signaling Pathway | |||
34 | B Cell Receptor Signaling Pathway | |||
35 | Prostate Cancer | |||
36 | Signaling Pathways in Glioblastoma | |||
37 | TSLP Signaling Pathway | |||
38 | IL17 signaling pathway | |||
39 | IL-7 Signaling Pathway | |||
40 | Regulation of Microtubule Cytoskeleton | |||
41 | TWEAK Signaling Pathway | |||
42 | FSH signaling pathway | |||
43 | Leptin signaling pathway | |||
44 | TSH signaling pathway | |||
45 | RANKL/RANK Signaling Pathway | |||
46 | Integrated Breast Cancer Pathway | |||
47 | SREBP signalling | |||
48 | Integrated Cancer pathway | |||
49 | IL-1 signaling pathway | |||
50 | Metabolism of nitric oxide | |||
51 | Integrin-mediated Cell Adhesion | |||
52 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
53 | MicroRNAs in cardiomyocyte hypertrophy | |||
54 | Angiogenesis | |||
55 | TOR Signaling | |||
56 | Regulation of toll-like receptor signaling pathway | |||
57 | AMPK Signaling | |||
58 | Androgen receptor signaling pathway | |||
59 | IL-5 Signaling Pathway | |||
60 | DNA Damage Response | |||
61 | ErbB Signaling Pathway | |||
62 | Senescence and Autophagy in Cancer | |||
63 | G1 to S cell cycle control | |||
64 | Sandbox Pathway | |||
65 | Wnt Signaling Pathway and Pluripotency | |||
66 | MAPK Signaling Pathway | |||
67 | Bladder Cancer | |||
68 | Mammary gland development pathway - Involution (Stage 4 of 4) | |||
69 | Pre-NOTCH Expression and Processing | |||
70 | ATM Signaling Pathway | |||
71 | Amyotrophic lateral sclerosis (ALS) | |||
72 | Retinoblastoma (RB) in Cancer | |||
73 | Spinal Cord Injury | |||
74 | Gastric cancer network 2 | |||
75 | Metastatic brain tumor | |||
76 | Alzheimers Disease | |||
77 | Intrinsic Pathway for Apoptosis | |||
78 | Factors involved in megakaryocyte development and platelet production | |||
79 | Cell Cycle | |||
80 | Cell Cycle Checkpoints | |||
81 | Apoptosis Modulation and Signaling | |||
82 | Folate Metabolism | |||
83 | TP53 Network | |||
84 | Fluoropyrimidine Activity | |||
85 | miRNAs involved in DNA damage response | |||
86 | miRNA Regulation of DNA Damage Response | |||
87 | SIDS Susceptibility Pathways | |||
88 | Apoptosis Modulation by HSP70 | |||
89 | FAS pathway and Stress induction of HSP regulation | |||
90 | Signaling by Hippo | |||
91 | Parkinsons Disease Pathway | |||
92 | Allograft Rejection | |||
93 | Signalling by NGF | |||
94 | Regulation of Apoptosis | |||
95 | Apoptotic execution phase | |||
96 | TGF Beta Signaling Pathway | |||
97 | Oxidative Stress | |||
98 | Myometrial Relaxation and Contraction Pathways | |||
99 | IL1 and megakaryotyces in obesity | |||
100 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
101 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
102 | Hair Follicle Development: Induction (Part 1 of 3) | |||
103 | Selenium Metabolism and Selenoproteins | |||
104 | Cytosolic sensors of pathogen-associated DNA | |||
105 | Fc epsilon receptor (FCERI) signaling | |||
106 | Transcriptional Regulation of White Adipocyte Differentiation | |||
107 | Signaling by the B Cell Receptor (BCR) | |||
108 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
109 | Structural Pathway of Interleukin 1 (IL-1) | |||
110 | EBV LMP1 signaling | |||
111 | Aryl Hydrocarbon Receptor | |||
112 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
113 | Neural Crest Differentiation | |||
114 | TCR signaling | |||
115 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
116 | Interleukin-1 signaling | |||
117 | Interleukin-1 processing | |||
118 | Vitamin B12 Metabolism | |||
119 | Selenium Micronutrient Network | |||
120 | Osteopontin Signaling |